Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24278544 | 0.86 | CHRNA7 (0.36) | CHRNA7OPRK1HTR3EHTR3BHTR3A | |
| SCHEMBL24278760 | 0.81 | CHRNA7 (0.40) | CHRNA7OPRK1HTR3EHTR3BHTR3A | |
| SCHEMBL24278756 | 0.80 | EDNRA (0.39) | CHRNA7OPRK1HTR3EHTR3BHTR3A | |
| SCHEMBL27052423 | 0.74 | CHRNA7 (0.50) | CHRNA7OPRK1HTR3EHTR3BHTR3A | |
| SCHEMBL24278780 | 0.74 | CHRNA7 (0.50) | CHRNA7OPRK1HTR3EHTR3BHTR3A | |
| SCHEMBL25755352 | 0.74 | CHRNA7 (0.50) | CHRNA7OPRK1HTR3EHTR3BHTR3A | |
| SCHEMBL25795484 | 0.73 | CHRNA7 (0.49) | CHRNA7OPRK1HTR3EHTR3BHTR3A | |
| SCHEMBL27105317 | 0.73 | CHRNA7 (0.49) | CHRNA7OPRK1HTR3EHTR3BHTR3A | |
| SCHEMBL27105316 | 0.73 | CHRNA7 (0.49) | CHRNA7OPRK1HTR3EHTR3BHTR3A | |
| SCHEMBL27053449 | 0.73 | CHRNA7 (0.49) | CHRNA7OPRK1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067763-A1 | SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER | MITSUI CHEMICALS, INC. (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240067763-A1 | SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER | MITSUI CHEMICALS, INC. (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240025838-A1 | ESTER COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240025838-A1 | ESTER COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-4206182-A1 | ESTER COMPOUND | Mitsui Chemicals, Inc. (JP) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022045231-A1 | ESTER COMPOUND | 三井化学株式会社 | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025838-A1 | ESTER COMPOUND | NR1H3, CYP4A11, H1-4 | CHRNA7 3219/4885OPRK1 662/4885HTR3E 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.